Status:
COMPLETED
Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block
Lead Sponsor:
Zulekha Hospitals
Conditions:
Regional Anesthesia Morbidity
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
Dexmedetomidine is recommended over fentanyl as adjunctive medication to bupivacaine for saddle block spinal anesthesia in anal surgeries and procedures.
Detailed Description
Objectives: A saddle spinal block is a viable choice for anal surgeries. This technique effectively maintains balanced hemodynamics, and fast recovery, and prevents irrelevant motor blocks in both lim...
Eligibility Criteria
Inclusion
- both sexes
- aged between 20 and 60
- classified as II \& ASA-I
- scheduled for elective anal surgeries
Exclusion
- subjects who refused to participate
- uncontrolled hypertension
- BMI \> 30 kg/m2
- heart failure (class IV or III) based on the New York Heart Association (NYHA)
- uncorrected coagulopathy
- any study's drug allergy
- drug abuse
- neuropathy
- any spinal anesthesia contraindication (such as infection or a pelvic fracture)
Key Trial Info
Start Date :
April 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 4 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT06216197
Start Date
April 3 2021
End Date
December 4 2022
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar faculty of medicine
Cairo, Egypt, 12546